Home/Pipeline/Ampholipad

Ampholipad

Post‑surgical pain

Commercial (China)Approved

Key Facts

Indication

Post‑surgical pain

Phase

Commercial (China)

Status

Approved

Company

Taiwan Liposome Company

About Taiwan Liposome Company

Taiwanese biotech leveraging next‑gen lipid delivery for pain, metabolic and cell‑therapy medicines.

View full company profile

Therapeutic Areas

Orthopedics Pain Management Metabolic Disorders Immune Disorders Infectious Diseases Regenerative Medicine